Table 1 Demographic and clinical characteristics by treatment cohort.
1st line mono-IO (n = 442) | 1st line chemo-IO (n = 915) | P-valuea | |
|---|---|---|---|
Age at treatment start, years, median (range) | 72 (38, 85) | 68 (33, 85) | <0.001 |
Gender, n (%) | 0.001 | ||
Female | 251 (57) | 427 (47) | |
Male | 191 (43) | 488 (53) | |
Race, n (%) | 0.1 | ||
Asian | 5 (1) | 11 (1) | |
Black or African American | 19 (4) | 60 (7) | |
Other | 65 (15) | 144 (16) | |
White | 322 (73) | 610 (67) | |
Missing | 31 (7) | 90 (10) | |
Smoking history, n (%) | 0.004 | ||
Yes | 418 (95) | 822 (90) | |
No | 24 (5) | 93 (10) | |
Practice type, n (%) | 0.3 | ||
Academic | 31 (7) | 50 (5) | |
Community | 411 (93) | 865 (95) | |
Advanced stage at diagnosisb, n (%) | <0.001 | ||
Yes | 292 (66) | 754 (82) | |
No | 143 (32) | 150 (16) | |
Not reported | 7 (2) | 11 (1) | |
ECOG performance statusc, n (%) | <0.001 | ||
0 | 88 (20) | 251 (27) | |
1 | 163 (37) | 332 (36) | |
2+ | 107 (24) | 144 (16) | |
Missing | 84 (19) | 188 (21) | |
Tumor type, n (%) | 0.02 | ||
Lung adenocarcinoma | 346 (78) | 773 (84) | |
Lung non-small cell lung carcinoma (nsclc) (nos) | 64 (14) | 93 (10) | |
Other | 32 (7) | 49 (5) | |
Tissue of origin, n (%) | 0.3 | ||
Lung | 211 (48) | 426 (47) | |
Lymph node | 60 (14) | 125 (14) | |
Brain | 37 (8) | 52 (6) | |
Bone | 19 (4) | 55 (6) | |
Other/unknown | 115 (26) | 257 (28) | |
TMB, n (%) | <0.001 | ||
Low (<10 mut/Mb) | 227 (51) | 583 (64) | |
High (≥10 mut/Mb) | 215 (49) | 332 (36) | |
PD-L1 expression, n (%) | <0.001 | ||
No (<1% TPS) | 16 (7) | 184 (38) | |
Low (1–49% TPS) | 33 (15) | 170 (36) | |
High (≥50% TPS) | 174 (78) | 124 (26) | |
Missing | 219 | 437 | |
Total number of lines of therapy received, n (%) | 0.4 | ||
1 | 319 (72) | 644 (70) | |
2 | 85 (19) | 171 (19) | |
3+ | 38 (9) | 100 (11) | |
Class of 2nd line therapy received, n (%) | <0.001 | ||
Chemotherapy alone | 48 (39) | 78 (29) | |
IO-Chemo combination | 23 (19) | 23 (8) | |
Immunotherapy alone | 21 (17) | 18 (7) | |
Other | 31 (25) | 152 (56) |
